← Leaderboards
Reuben Kapur
Indiana University Indianapolis
$21,257,649
Attributed
$24,614,910
Total exposure
17
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,526,519 · 18
By mechanism
R01$22,507,435 · 10
U54$3,911,609 · 1
R21$1,024,298 · 3
T32$598,415 · 1
R56$377,500 · 1
P30$107,262 · 2
Top collaborators
- Rebecca J Chan5 shared
- Karen Elizabeth Pollok5 shared
- Herman O Sintim4 shared
- Roland W. Herzog3 shared
- Jianjian Shi2 shared
- Ngoc Tung Tran2 shared
- Mervin C. Yoder1 shared
- Ji Zhang1 shared
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Jianjian Shi$1,079,465
- Ji Zhang$2,565,300
- David W. Clapp$30,065,006
- Lisa Deng Yuen$167,577
- James Patrick Ropa$434,641
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMutationSignal TransductionPathway InteractionsGrowthMediatingLeukemiaIn VivoRegulationHematopoietic Stem CellsMutantIn VitroMyeloproliferative DiseasePlayHematopoieticClinical TrialsLeukemogenesisBaseInsightHematopoiesisFlt3 GeneGeneticBone MarrowEpigenetic Process
Grant awards (70)
Hematopoietic stem and progenitor cell regulation for enhanced clinical efficacy$856,540
U54 · FY2025 · DK · contact PI
Regulation of hematopoietic stem cells under low oxygen tension$792,498
R01 · FY2025 · HL · contact PI
Hypoxia's role in regulating stressed hematopoietic stem cells$615,543
R01 · FY2025 · DK · contact PI
3H-pyrazolo[4,3-f]quinoline-containing compounds as selective and tunable protein kinase inhibitors$461,983
R01 · FY2025 · CA
Role of p21 activated kinase in Leukemogenesis$369,310
R01 · FY2025 · CA · contact PI
Hematopoiesis & Hematologic Malignancies$75,139
P30 · FY2025 · CA · contact PI
Hematopoietic stem and progenitor cell regulation for enhanced clinical efficacy$772,128
U54 · FY2024 · DK · contact PI
Hypoxia's role in regulating stressed hematopoietic stem cells$684,735
R01 · FY2024 · DK · contact PI
3H-pyrazolo[4,3-f]quinoline-containing compounds as selective and tunable protein kinase inhibitors$434,910
R01 · FY2024 · CA
Role of p21 activated kinase in Leukemogenesis$350,846
R01 · FY2024 · CA · contact PI
Basic Sciences Studies on Gene Therapy of Blood Diseases$176,297
T32 · FY2024 · HL
Hematopoietic stem and progenitor cell regulation for enhanced clinical efficacy$772,128
U54 · FY2023 · DK · contact PI
3H-pyrazolo[4,3-f]quinoline-containing compounds as selective and tunable protein kinase inhibitors$452,225
R01 · FY2023 · CA
Role of Shp2 in FLT3-ITD induced leukemogenesis$366,582
R01 · FY2023 · CA · contact PI
Role of p21 activated kinase in Leukemogenesis$361,924
R01 · FY2023 · CA · contact PI
Basic Sciences Studies on Gene Therapy of Blood Diseases$241,320
T32 · FY2023 · HL
Dual anti-leukemic and cardio protective role for ROCK$181,543
R21 · FY2023 · CA · contact PI
Hematopoiesis and Hematological Malignancies Program$32,123
P30 · FY2023 · CA · contact PI
Hematopoietic stem and progenitor cell regulation for enhanced clinical efficacy$738,685
U54 · FY2022 · DK · contact PI
Hyperglycemia mediated myeloproliferative disease$582,811
R01 · FY2022 · HL · contact PI
Targeting Novel Pathways in JMML$542,416
R01 · FY2022 · HL · contact PI
3H-pyrazolo[4,3-f]quinoline-containing compounds as selective and tunable protein kinase inhibitors$495,845
R01 · FY2022 · CA
Role of Shp2 in FLT3-ITD induced leukemogenesis$366,582
R01 · FY2022 · CA · contact PI
Role of p21 activated kinase in Leukemogenesis$361,924
R01 · FY2022 · CA · contact PI
Dual anti-leukemic and cardio protective role for ROCK$222,296
R21 · FY2022 · CA · contact PI
Basic Sciences Studies on Gene Therapy of Blood Diseases$180,798
T32 · FY2022 · HL
Novel drug to treat poor prognosis AML$180,259
R21 · FY2022 · CA · contact PI
Hematopoietic stem and progenitor cell regulation for enhanced clinical efficacy$772,128
U54 · FY2021 · DK · contact PI
Hyperglycemia mediated myeloproliferative disease$582,811
R01 · FY2021 · HL · contact PI
Targeting Novel Pathways in JMML$542,416
R01 · FY2021 · HL · contact PI
Role of Shp2 in FLT3-ITD induced leukemogenesis$374,063
R01 · FY2021 · CA · contact PI
Role of p21 activated kinase in Leukemogenesis$369,310
R01 · FY2021 · CA · contact PI
Novel drug to treat poor prognosis AML$234,662
R21 · FY2021 · CA · contact PI
Hyperglycemia mediated myeloproliferative disease$577,831
R01 · FY2020 · HL · contact PI
Targeting Novel Pathways in JMML$534,541
R01 · FY2020 · HL · contact PI
Role of Shp2 in FLT3-ITD induced leukemogenesis$374,063
R01 · FY2020 · CA · contact PI
Hyperglycemia mediated myeloproliferative disease$586,415
R01 · FY2019 · HL · contact PI
Targeting Novel Pathways in JMML$534,541
R01 · FY2019 · HL · contact PI
Role of Shp2 in FLT3-ITD induced leukemogenesis$374,063
R01 · FY2019 · CA · contact PI
Role of p21 activated kinase in Leukemogenesis$323,700
R01 · FY2018 · CA · contact PI
Role of p21 activated kinase in Leukemogenesis$323,700
R01 · FY2017 · CA · contact PI
HSC-Independent Mechanisms Underlying JMML$205,538
R21 · FY2017 · CA · contact PI
Novel Mechanisms of C-Kit Regulation in Mast Cells$390,000
R01 · FY2016 · HL · contact PI
Role of p21 activated kinase in Leukemogenesis$323,700
R01 · FY2016 · CA · contact PI
Novel Mechanisms of C-Kit Regulation in Mast Cells$384,150
R01 · FY2015 · HL · contact PI
Role of p21 activated kinase in Leukemogenesis$323,700
R01 · FY2015 · CA · contact PI
Role of Shp2 in FLT3-ITD-Induced Leukemogenesis$319,550
R01 · FY2015 · CA
Novel Mechanisms of C-Kit Regulation in Mast Cells$382,200
R01 · FY2014 · HL · contact PI
Role of p21 activated kinase in Leukemogenesis$323,700
R01 · FY2014 · CA · contact PI
Role of Shp2 in FLT3-ITD-Induced Leukemogenesis$309,964
R01 · FY2014 · CA
Novel Mechanisms of C-Kit Regulation in Mast Cells$371,280
R01 · FY2013 · HL · contact PI
Role of Vav and Rac in KIT oncogenesis$362,855
R01 · FY2013 · HL · contact PI
Role of Shp2 in FLT3-ITD-Induced Leukemogenesis$300,377
R01 · FY2013 · CA
Role of Vav and Rac in KIT oncogenesis$381,150
R01 · FY2012 · HL · contact PI
Role of Shp2 in FLT3-ITD-Induced Leukemogenesis$319,550
R01 · FY2012 · CA
Role of Vav and Rac in KIT oncogenesis$385,000
R01 · FY2011 · HL · contact PI
Role of Shp2 in FLT3-ITD-Induced Leukemogenesis$319,550
R01 · FY2011 · CA
Mechanisms of adhesion and growth control in stem cells$426,677
R01 · FY2010 · HL · contact PI
Role of Vav and Rac in KIT oncogenesis$385,000
R01 · FY2010 · HL · contact PI
Mechanisms of adhesion and growth control in stem cells$418,735
R01 · FY2009 · HL · contact PI
Role of Vav and Rac in KIT oncogenesis$385,000
R01 · FY2009 · HL · contact PI
Novel Mechanisms of C-Kit Regulation in Mast Cells$366,766
R01 · FY2009 · HL · contact PI
Mechanisms of adhesion and growth control in stem cells$377,500
R56 · FY2008 · HL · contact PI
Novel Mechanisms of C-Kit Regulation in Mast Cells$367,766
R01 · FY2008 · HL · contact PI
Novel Mechanisms of C-Kit Regulation in Mast Cells$367,766
R01 · FY2007 · HL · contact PI
Mechanisms of adhesion and growth control in stem cells$356,753
R01 · FY2007 · HL · contact PI
Novel Mechanisms of C-Kit Regulation in Mast Cells$378,750
R01 · FY2006 · HL · contact PI
Mechanisms of adhesion and growth control in stem cells$367,408
R01 · FY2006 · HL · contact PI
Mechanisms of adhesion and growth control in stem cells$376,250
R01 · FY2005 · HL
Mechanisms of adhesion and growth control in stem cells$376,250
R01 · FY2004 · HL